The arterial blood gas kits market size is projected to reach US$ 1,298.03 million by 2031 from US$ 712.46 million in 2023. The market is expected to register a CAGR of 7.8% during 2023–2031. The development of safe and automated kits, and the integration of electronic medical records is likely to remain a key trend in the market.
The increasing prevalence of kidney diseases and metabolic diseases, technological advancements in arterial blood gas kits, and growing emphasis on personalized medicines in developed countries are the factors favoring the arterial blood gas kits market progress. The surging adoption of point-of-care diagnostics in emerging countries is also expected to benefit the market in the coming years.
India is expected to register the highest CAGR in the global arterial blood gas kits market during 2023–2031. In India, respiratory diseases are responsible for the poor quality of life among the people. A surge in the awareness of respiratory diseases such as asthma, COPD, and respiratory syndrome would offer lucrative growth opportunities to the market in the country. Respiratory distress syndrome (RDS) is a common breathing disorder observed in premature babies in India, causing 150,000 deaths annually. According to a report by the Global Burden of Disease (GBD), chronic obstructive pulmonary disease (COPD) is the second leading cause of death and disability-adjusted life years (DALYs) in India. As per the Lancet Global Health data released in April 2020, asthma was a cause of illness in ~300 million people in the world, and 37.9 million of these people were Indians. Statistics by the Government of India indicate that India, the world's second-most populated country, has seen a tremendous demographic shift in the last 50 years, with nearly a tripling of the elderly population over the age of 60. According to a BQ Prime article, ~138 million people in India aged 60 years and above in 2021, and the number is expected to reach 194 million by the end of 2031. The elderly population in India is estimated to surpass the population of children under 14 years by 2050. Aging is an independent predictor of acute respiratory disease, particularly in critically ill older individuals. For instance, Dr. M.G.R. Educational and Research Institute University is conducting a study named the "Analysis of Arterial Blood Gas (ABG) Profile in Patients with Acute Heart Failure in Tertiary Care Centre at ACS Medical College," in which they studied the pattern of arterial blood gas results in heart failure patients that are admitted to tertiary care center. Thus, the arterial blood gas kits market in India is likely to flourish in the coming years due to the growing geriatric population and ongoing research activities in respiratory care.
Respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and pneumonia lead to a huge burden on public healthcare systems in various countries across the world. Infections, smoking, and genetic factors can cause serious respiratory complications. In 2021, the American Lung Association ranked COPD third among the leading causes of death in the US, and over 16.4 million people are diagnosed with the condition that year. The article "Effectiveness of a Home Telemonitoring Program for Patients with Chronic Obstructive Pulmonary Disease in Germany," published by the National Library of Medicine in 2022, estimates that Germany reported ∼6 million COPD cases. The article titled "What Knows a Frail Swiss Population About Chronic Obstructive Pulmonary Disease?", published in 2021, estimated that ~400,000 people were affected by COPD in Switzerland. As per the Asthma and Allergy Foundation of America, ∼26 million people in the US suffered from asthma in 2022. The United Nations International Children's Emergency Fund (UNICEF) stated that nearly 1,400 per 100,000 children, i.e., 1 case per 71 children, are diagnosed with pneumonia every year. Breathing issues and oxygen shortages are common in patients suffering from respiratory disorders. Arterial blood gas (ABG) tests are performed to measure oxygen and carbon dioxide gases dissolved in blood. The test serves as a basis of care delivered to patients suffering from acute and chronic respiratory disease. Thus, the surging incidences of acute and chronic respiratory diseases propel the demand for arterial blood gas test kits.
The inability to run rapid diagnoses is a significant cause of deaths resulting from various diseases in emerging countries. An effective diagnostic infrastructure requires stable electrical power, sophisticated instruments, expensive reagents, and highly trained professionals; thus, diagnoses in developing countries are often limited by the unavailability of these resources. Moreover, the existing diagnostic capabilities result in long assay times, rendering them unsuitable for settings with limited resource availability. Point-of-care testing offers immediate diagnostic results at or near the patient's location, enabling rapid clinical decision-making, streamlined workflows, and enhanced patient outcomes. The need for timely interventions, efficient diagnostic processes, and personalized healthcare delivery fuels the demand for decentralized testing solutions. Point-of-care arterial blood gas kits allow healthcare providers to perform critical diagnostic tests at the patient's bedside, in emergency departments, or in remote settings, facilitating on-the-spot assessment of blood gas parameters, electrolyte levels, and acid-base status. The accessibility and immediacy of point-of-care analyzers empower clinicians to promptly initiate appropriate treatments, monitor patient responses in real-time, and optimize clinical decision-making in acute care scenarios. The shift toward point-of-care diagnostics also drives technological advancements in arterial blood gas kits as manufacturers focus on developing compact, automated, and easy-to-use devices that deliver accurate and fast results. The seamless integration of point-of-care analyzers into healthcare workflows enhances operational efficiency, reduces turnaround times, and improves overall patient care quality. Thus, as healthcare settings embrace the advantages of point-of-care testing, the demand for portable and user-friendly arterial blood gas kits is rising in developing countries, which is likely to create growth opportunities for the market in the coming years.
Key segments that contributed to the derivation of the arterial blood gas kits market analysis are syringe type, usage, type, needle gauge, syringe volume , application, and end user.
The geographic scope of the arterial blood gas kits market report is mainly divided into five regions: North America, Asia Pacific, Europe, the Middle East & Africa, and South & Central America. North America dominated the market in 2023. The North America arterial blood gas kits market has been analyzed on the basis of the US, Canada, and Mexico. Increasing prevalence and incidence of chronic heart and respiratory diseases result in the increased use of arterial blood gas test kits in North American countries. The US held the largest share of the arterial blood gas kits market in North America in 2023. The growing prevalence of chronic diseases necessitating arterial blood gas analysis, including respiratory failure, acute respiratory distress syndrome (ARDS), asthma, diabetic ketoacidosis, renal tubular acidosis, heart failure (HF), and congenital metabolic diseases, is the major factor contributing to the largest share of the US in the arterial blood gas kits market. Additionally, the rising number of collaboration initiatives by research organizations to explore innovative therapeutic applications are projected to accelerate the demand for arterial blood gas kits. Radiometer, BD, and Siemens Healthineers AG are among the major arterial blood gas kit manufacturers operating across North America.
The regional trends and factors influencing the Arterial Blood Gas Kits Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Arterial Blood Gas Kits Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 712.46 Million |
| Market Size by 2031 | US$ 1,298.03 Million |
| Global CAGR (2023 - 2031) | 7.8% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Syringe Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Arterial Blood Gas Kits Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Arterial Blood Gas Kits Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The arterial blood gas kits market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the arterial blood gas kits market are listed below:
The "Arterial Blood Gas Kits Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
The arterial blood gas kits market is anticipated to record a CAGR of 7.8% during 2023–2031.
BD, Radiometer Medical ApS, Vyaire Medical Inc, Opti Medical Systems, Siemens Healthineers AG, AdvaCare Pharma USA LLC, Becton Dickinson and Co, ICU Medical Inc, SunMed Group Holdings LLC ( AirLife), Trudell Healthcare Solutions Inc, Siemens Healthineers, SARSTEDT AG & Co KG, Lepu Medical Technology Beijing Co Ltd, and Levram Lifesciences Pvt. Ltd. are among the key players operating in the market.
North America dominated the market in 2023.
The increasing incidence of respiratory diseases and rising number of admissions to emergency units in hospitals are among the most influential factors bolstering the market growth.
The development of safe & automated kits and integration of electronic medical records are likely to remain key trends in the arterial blood gas kits market.
The arterial blood gas kits market value is estimated to reach US$ 1,298.03 million in 2031.
The development of safe & automated kits and integration of electronic medical records are likely to remain key trends in the arterial blood gas kits market.